SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis.
about
Topical pimecrolimus for eczemaNeuroimmunological mechanism of pruritus in atopic dermatitis focused on the role of serotoninSystemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patientsNonsteroidal Topical Immunomodulators in Allergology and DermatologyThe diagnosis and graded therapy of atopic dermatitisEfficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials.Pimecrolimus does not affect Langerhans cells in murine epidermis.Therapeutic options for chronic hand dermatitis.The effects of treatment on itch in atopic dermatitisWhat's new in atopic dermatitis?What is new in therapy?Pharmacoeconomics of drug therapy for atopic dermatitis.Calcineurin inhibitors and rapamycin: cancer protection or promotion?New treatments for atopic dermatitis.Treatment principles of atopic dermatitis.Pimecrolimus: a review.Pimecrolimus for the treatment of inflammatory skin disease.Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis.Macrolactam immunomodulators (tacrolimus and pimecrolimus): new horizons in the topical treatment of inflammatory skin diseases.The role of topical calcineurin inhibitors in atopic dermatitis.Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.Problem-based learning: a review of current issues relevant to physiotherapy education.Recent developments in the treatment of adult atopic dermatitis.A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema.Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus.A systematic review of the safety of topical therapies for atopic dermatitis.How to deal with multiple treatment or dose groups in randomized clinical trials?Pimecrolimus versus topical corticosteroids in dermatology.Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials.Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis.Cutaneous dendritic cells in allergic inflammation.Pimecrolimus for psoriasis.Pimecrolimus, a topical calcineurin inhibitor used in the treatment of atopic eczema.An update on current pharmacotherapy options in atopic dermatitis.Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out?'EASIdig'--a digital tool to document disease activity in atopic dermatitis.Difficult to control atopic dermatitisUse of the Self-Administered Eczema Area and Severity Index by parent caregivers: results of a validation study.Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and metronidazole 0.75% gel in the treatment of seborrhoeic dermatitis: a randomized clinical study.Ascomycin: an advance in the management of atopic dermatitis.
P2860
Q24243250-9A2AA5EF-8B25-43DD-947C-7D95AF90DA8EQ24628657-3A5E3528-8150-4710-B98C-DA57FD258466Q24675365-670EA897-4730-4FF8-8EB8-D502F32D2D57Q26752832-5BAA9A19-F898-4C07-A865-2604D818E6A0Q27025032-DF866427-BB91-46FB-87C5-AE13E0337AB1Q31149849-DC4A9385-1E02-4481-9EAD-2156A14E38F7Q34276712-15912E49-1E0F-4146-9959-DC9833FDD2E2Q34325706-4BCC1986-6E28-4E0E-A035-C09B28039D81Q34336696-A9FB9FB9-43D2-448C-BB1E-EA2067924C3EQ34352747-CBB174E5-8CA1-42A2-9F49-E3184357607BQ34459067-B655CED7-7F24-49C6-98A4-844779F7D361Q34544712-32A3858D-31FA-4342-976C-34F2438D28A8Q34578721-FD27414D-715D-4668-9BEE-A7988FFD8E42Q34592295-BF28EA83-590E-410B-A011-7F5FD36E9CE3Q34600248-D893023A-5213-4B37-99AA-323E954A3419Q35206755-980F9F96-D5BE-4883-8EB3-D7D7BBA2B45FQ35688189-7CBF3843-2389-4DDE-B4D7-54D227C8E395Q35809490-2813607E-4D73-4DFA-AC0C-AD8F88022424Q35922000-AE7693C7-D571-4F67-8EBE-5A4829440407Q35952647-5A5A00F7-13DD-4263-9408-46C31F812745Q36222741-820969E6-8334-46D5-878B-2FEDDFB412B0Q36356956-5D9CFF4C-B93B-46E4-AEE9-27A6F5A5227CQ36459429-081859D8-EDB4-4DAE-864A-87AE1328C8D0Q36480608-85CB7027-B037-44F0-9EBC-A055FD3162E7Q36574341-B8718ACC-85C3-4883-B5BA-9734E705C6E4Q36708358-66AF6DF0-4D8B-471E-8DE2-06F6BB874F44Q36772942-94F5A505-C8E0-4410-BF35-2599F6C2DEF5Q36895865-E014BE2B-F914-43D5-AE79-EBCC1DDFB971Q37731539-D901E3F8-4785-4E4F-93C7-8197796FA42DQ37977478-6CEF6B6D-D6DD-40F2-BF8F-55E0B5E4DDBEQ38026993-CFC5F4F1-766A-4767-ABDB-D2BED2CC1119Q38086585-F24C4E30-7E4D-4738-8718-6B7CA684BF04Q38123240-E71E677B-C973-4A4E-9F58-917D443437BCQ38210447-3E2A3C83-FEF9-4E3F-B1E4-F02D66FCF8A1Q38452688-CBEF9741-FE3F-4677-9636-E155129BC6E0Q39995897-28C88743-1F80-4DFE-9B75-8762A0E768E1Q40473325-0B5ECB9C-87A3-47AD-90BA-FB5CB900D2C8Q40619262-D5525F93-C898-4E2F-A1C3-E04966BD841BQ43232059-260313A8-A11C-4B58-B4B1-E99F2C819F9AQ43572222-28F8AD35-0E09-4AD4-AF1E-4BC111C56982
P2860
SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis.
@en
SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis.
@nl
type
label
SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis.
@en
SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis.
@nl
prefLabel
SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis.
@en
SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis.
@nl
P2093
P1476
SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis.
@en
P2093
Berth-Jones J
Christophers E
Hedgecock S
P2860
P304
P356
10.1046/J.1365-2133.2001.04134.X
P407
P577
2001-04-01T00:00:00Z